EMD-71328

Single-particle
2.92 Å
EMD-71328
3D View Gallery
Deposition: 20/06/2025
Map released: 21/01/2026
Last modified: 29/04/2026
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-71328
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 9p6x summary report (pdf.gz) Map and 9p6x FULL report (pdf.gz)
EMICSS annotations (xml)

Structure of EBOV glycoprotein in complex with Nanosota-EB1 and EB2

EMD-71328

Single-particle
2.92 Å
EMD-71328
3D View Gallery
Deposition: 20/06/2025
Map released: 21/01/2026
Last modified: 29/04/2026
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Vicugna pacos, Ebola virus - Mayinga, Zaire, 1976, Ebola virus
Sample: EBOV glycoprotein in complex with Nanosota-EB1 and EB2
Fitted models: 9p6x

Deposition Authors: Bu F, Ye G, Li F, Li F
A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections.
Bu F, Ye G, Morsheimer K, Turner-Hubbard H, Eaton B, Anantpadma M, Bheemanapally K, Tan C, Davey R, Li F
(2026) PLoS Pathog , 22 , e1013878 - e1013878
PUBMED: 41592114
DOI: doi:10.1371/journal.ppat.1013878
ISSN: 1553-7374